Filing Details

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

CUSIP No. 43906K 100

1

Name of Reporting Person
Gilead Sciences, Inc.

2

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

o

(b)

o

3

SEC Use Only

4

Citizenship or Place of Organization
State of Delaware

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power
2,092,799

6

Shared Voting Power
0

7

Sole Dispositive Power
2,092,799

8

Shared Dispositive Power
0

9

Aggregate Amount Beneficially Owned by Each Reporting Person
2,092,799

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

11

Percent of Class Represented by Amount in Row (9)
7.2%(1)

12

Type of Reporting Person (See Instructions)
CO

Item 1.

(a)

Name of Issuer
HOOKIPA Pharma Inc.

(b)

Address of Issuers Principal Executive Offices
350 Fifth Avenue, 72nd Floor, Suite 7240
New York, NY 10118

Item 2.

(a)

Names of Persons Filing
Gilead Sciences, Inc.

(b)

Address of Principal Business Office or, if none, Residence
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California, 94404

(c)

Citizenship
State of Delaware

(d)

Title of Class of Securities
Common Stock, $0.0001 par value

(e)

CUSIP Number
43906K 100

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

N/A.

Item 4.

Ownership.

(a)

Amount beneficially owned:

2,092,799

(b)

Percent of class:

7.2%*

(c)

Number of shares as to which Gilead Sciences, Inc. has:

(i)

Sole power to vote or to direct the vote:

2,092,799

(ii)

Shared power to vote or to direct the vote:

0

(iii)

Sole power to dispose or to direct the disposition of:

2,092,799

(iv)

Shared power to dispose or to direct the disposition of:

0

*

Percentage based on 29,061,468 shares of Common Stock outstanding as of December 11, 2020, as reported in in the Prospectus Supplement, dated as of December 8, 2020, filed pursuant to Rule 424(b)(5) by the Issuer with the U.S. Securities and Exchange Commission (SEC) on December10, 2020.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following   o

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

N/A.

Item 8.

Identification and Classification of Members of the Group.

N/A.

Item 9.

Notice of Dissolution of Group.

N/A.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

GILEAD SCIENCES, INC.

/s/ Brett Pletcher

Name: Brett Pletcher

Title: EVP, Corporate Affairs, General Counsel & Corporate Secretary